Your session is about to expire
← Back to Search
Dexamethasone for Multiple Myeloma
Study Summary
This trial is a phase I-II open label study testing a combination of pomalidomide, bendamustine, and dexamethasone as a treatment for relapsed or refractory multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the main conditions that doctors treat with Bendamustine?
"bendamustine, while most often used to treat ophthalmia, sympathetic, can also be helpful for branch retinal vein occlusion, macular edema and communicable diseases."
Could you provide an update on how many individuals are included in this clinical trial?
"This particular study is not recruiting patients at the moment, as evidenced by an original posting date of January 7th, 2013 and most recent update on July 23rd, 2018. However, there are 827 clinical trials for multiple myeloma and 673 trials for Bendamustine that are currently looking for participants."
Are people still being accepted into this clinical trial?
"This particular study is no longer recruiting patients. The trial was first posted on January 7th, 2013 and received its last edit on July 23rd, 2018. However, there are 827 other trials for multiple myeloma and 673 trials for Bendamustine that are still looking for participants."
What are the goals that researchers are hoping to achieve with this clinical trial?
"This clinical trial's primary outcome, which will be assessed after approximately 2 months, is the Maximum Tolerated Dose of Pomalidomide and Bendamustine. Secondary outcomes include Progression Free Survival (time from starting study therapy to disease progression or death), Time to Progression (time from response to disease progression), and Time to Next Therapy (time from starting study therapy to starting next therapy)."
Share this study with friends
Copy Link
Messenger